Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Non-small Cell Lung Cancer Age: Adult |
Dose: Tablet – 80 mg Frequency: once daily |
|
Indication: Non-small Cell Lung Cancer Age: Adult Condition: Hepatic impairment Mild (Total Bilirubin \< Upper Limit of Normal and Aspartate Aminotransferase 1-1.5 Upper Limit of Normal, or Total Bilirubin 1-1.5 Upper Limit of Normal and any Aspartate Aminotransferase) |
Dose: Tablet – 80 mg Frequency: once daily Note: No dose adjustment required |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Tablet – Safety and efficacy not established Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Adult Condition: Mild-to-moderate (CrCl 30-89 mL/min) |
Dose: Not specified Note: No dose adjustment required |
|
Age: Adult Condition: Severe or ESRD (CrCl less than 30 mL/min) |
Dose: Not specified Note: There is no recommended dose |
Administration
- Can be taken with or without food
- Take at same time each day
Side Effect
- Lymphopenia (63%)
- Thrombocytopenia (54%)
- Anemia (44%)
- Diarrhea (42%)
- Rash (41%)
- Neutropenia (33%)
- Dry skin (31%)
- Hyponatremia (26%)
- Nail toxicity (25%)
- ypermagnesemia (20%)
- Eye disorders (18%)
- Nausea (17%)
- Decreased appetite (16%)
- Constipation (15%)
- Pruritus (14%)
- Fatigue (14%)
- Cough (14%)
- Back pain (13%)
- Stomatitis (12%)
- Headache (10%)
- Venous thromboembolism (7%)
- Pneumonia (4%)
- Interstitial lung disease/pneumonitis (3.3%)
- QTc increased from baseline More than 60 msec (2.7%)
- Cardiomyopathy (1.4%)
- Keratitis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Strong CYP3A4 inducers (e.g. phenytoin, rifampicin, carbamazepine, St. John's wort)
|
Decreased exposure
|
|
Rosuvastatin
|
May increase AUC & Cmax
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store Osimertinib at room temperature between 20°C to 25°C. Safely throw away medicine that is out of date or that you no longer need. Keep Osimertinib and all medicines out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.